Editorial

2015: The Good The Bad The Ugly

After 2014, a year of first implementations of direct-acting antiviral therapies, 2015 brought even more changes and challenges in hepatitis C virus research, diagnosis, treatment and access.

We saw much good: approvals in difficult-to-treat genotypes, breakthrough designations for soon-to-come drugs that hold promise for underserved populations and a successful continuous updating of the HCV guidelines document jointly maintained by the AASLD and IDSA.

Yet there was the bad: real-world experiences with rapidly approved drugs proven to produce drug-drug interactions and unforeseen toxicities.

And the ugly seems to be getting uglier, with ongoing denials of treatment for patients who have not yet progressed in severity of their disease.

Please see my Looking Back, Looking Ahead article for a more detailed breakdown on what 2015 brought to our community and what I foresee in the coming year.

Michael S. Saag, MD
Co-Chief Medical Editor
HCV Next

After 2014, a year of first implementations of direct-acting antiviral therapies, 2015 brought even more changes and challenges in hepatitis C virus research, diagnosis, treatment and access.

We saw much good: approvals in difficult-to-treat genotypes, breakthrough designations for soon-to-come drugs that hold promise for underserved populations and a successful continuous updating of the HCV guidelines document jointly maintained by the AASLD and IDSA.

Yet there was the bad: real-world experiences with rapidly approved drugs proven to produce drug-drug interactions and unforeseen toxicities.

And the ugly seems to be getting uglier, with ongoing denials of treatment for patients who have not yet progressed in severity of their disease.

Please see my Looking Back, Looking Ahead article for a more detailed breakdown on what 2015 brought to our community and what I foresee in the coming year.

Michael S. Saag, MD
Co-Chief Medical Editor
HCV Next